Abbot Financial Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Abbot Financial Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,650	Closed	-$143K	–	137
2021 Q3	$143K	Buy	+10,650	New	+$174K	0.07%	132
2021 Q2	–	Sell	-8,650	Closed	-$208K	–	135
2021 Q1	$208K	Buy	+8,650	New	+$201K	0.09%	127
2020 Q3	–	Sell	-8,350	Closed	-$203K	–	135
2020 Q2	$203K	Buy	+8,350	New	+$138K	0.14%	108
2020 Q1	–	Sell	-8,550	Closed	-$226K	–	138
2019 Q4	$226K	Buy	+8,550	New	+$200K	0.14%	117
2019 Q3	–	Sell	-8,550	Closed	-$262K	–	127
2019 Q2	$262K	Buy	+8,550	New	+$180K	0.19%	105
2018 Q4	–	Sell	-8,800	Closed	-$460K	–	117
2018 Q3	$460K	Hold	8,800	–	–	0.34%	73
2018 Q2	$382K	Buy	8,800 +300	+4%	+$12.9K	0.3%	79
2018 Q1	$315K	Buy	+8,500	New	+$227K	0.25%	85

Other funds holding GTHX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Abbot Financial Management's GTHX Position: Q4 2021 in Review

Abbot Financial Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2021, closing a stake of 10,650 shares — an estimated $143K sold.

Abbot Financial Management first reported a position in GTHX in Q1 2018 and held it in 8 quarters. The position peaked at $460K in Q3 2018. 108 funds tracked by Wall St. Rank hold GTHX as of Q4 2021.

Abbot Financial Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Abbot Financial Management sold 10,650 G1 Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $143K.
Abbot Financial Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 8 quarters.
Abbot Financial Management's G1 Therapeutics, Inc. Common Stock position peaked at $460K in Q3 2018.
108 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Abbot Financial Management's 13F filing for Q4 2021, filed 15 Feb 2022.